JANX
Janux Therapeutics Inc
$46.5
Earnings Summary
Revenue | $0.44Mn |
Net Profits | $-28.06Mn |
Net Profit Margins | -6391.57% |
Highlights
Janux Therapeutics Inc’s revenue fell -82.56% since last year same period to $0.44Mn in the Q3 2024. On a quarterly growth basis, Janux Therapeutics Inc has generated -95.07% fall in its revenue since last 3-months.
Janux Therapeutics Inc’s net profit fell -142.56% since last year same period to $-28.06Mn in the Q3 2024. On a quarterly growth basis, Janux Therapeutics Inc has generated -370.87% fall in its net profits since last 3-months.
Janux Therapeutics Inc’s net profit margin fell -1290.7% since last year same period to -6391.57% in the Q3 2024. On a quarterly growth basis, Janux Therapeutics Inc has generated -9442.85% fall in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Janux Therapeutics Inc post its latest quarter earnings
EPS Estimate Current Quarter | -0.36 |
EPS Estimate Current Year | -0.36 |
Highlights
Janux Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.36 - a -15.06% fall from last quarter’s estimates.
Janux Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.36.
Key Ratios
Key ratios of the Janux Therapeutics Inc post its Q3 2024 earnings
Earning Per Share (EPS) | -0.51 |
Highlights
Janux Therapeutics Inc’s earning per share (EPS) fell -104% since last year same period to -0.51 in the Q3 2024. This indicates that the Janux Therapeutics Inc has generated -104% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2024-11-06 | -0.36 | -0.51 | -42.98% |
2024-08-07 | -0.31 | -0.11 | 64.52% |
2024-05-08 | -0.33 | -0.3 | 9.09% |
₹0 US Stocks a/c Opening Fee